Voyager Therapeutics Inc
NASDAQ:VYGR
Voyager Therapeutics Inc
Revenue
Voyager Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
Revenue
$250m
|
CAGR 3-Years
13%
|
CAGR 5-Years
101%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Voyager Therapeutics Inc's Revenue?
Revenue
250m
USD
Based on the financial report for Dec 31, 2023, Voyager Therapeutics Inc's Revenue amounts to 250m USD.
What is Voyager Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
101%
Over the last year, the Revenue growth was 511%. The average annual Revenue growth rates for Voyager Therapeutics Inc have been 13% over the past three years , 101% over the past five years .